2019
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.Peer-Reviewed Original ResearchConceptsRBC transfusion independenceLR-MDS patientsTransfusion independenceHMA initiationRBC transfusionClinical effectivenessReal-life clinical effectivenessRed blood cell transfusionLower-risk myelodysplastic syndromesLow-risk MDS patientsRisk MDS patientsBlood cell transfusionRisk myelodysplastic syndromesHMA therapyLR-MDSCell transfusionMost patientsDisease courseMDS patientsMedicare databaseMyelodysplastic syndromePopulation-level estimatesLower oddsTransfusionPatients
2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review Of Hematology 2017, 10: 345-364. PMID: 28277851, DOI: 10.1080/17474086.2017.1297704.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsErythropoiesis stimulating agentsMyelodysplastic syndromeLR-MDSImmunosuppressive therapyTreatment modalitiesLower-risk myelodysplastic syndromesTGF-β pathway inhibitorCombination treatment modalitiesLR-MDS patientsPromising investigational agentsSubset of patientsAvailable therapeutic modalitiesGoals of careStandard therapeutic optionPredictors of responseCurrent treatment modalitiesAcute myeloid leukemiaQuality of lifeBone marrow failureRisk assessment toolSymptom controlBlood cytopeniasInvestigational agentsTherapeutic optionsClinical behavior